Anda di halaman 1dari 2

Celdara Medical Receives $2M Phase II SBIR Grant

Celdara Medical, LLC today announced that the National Cancer Institute of the National
Institutes of Health has awarded a two-year, $2 million Phase II Small Business Innovation
Research grant to fund the companys development of a B cell focused immunotherapy to treat
melanoma and other cancers.

Lebanon, NH, June 19, 2017 -- Celdara Medical, LLC today announced that the National Cancer
Institute of the National Institutes of Health has awarded a two-year, $2 million Phase II Small
Business Innovation Research grant to fund the companys development of a B cell focused
immunotherapy to treat melanoma and other cancers. The biologic, CM-JG01, targets the
previously untapped potential of B cells to induce a potent tumoricidal T-cell response. This project
will be developed in partnership with Dr. Jacques Galipeau at the University of Wisconsin.

Dr. Jake Reder, Co-founder and Chief Executive Officer of Celdara Medical, remarked, We are
extremely thankful to the NCI for their support. We now have an important opportunity to advance
the development of this innovative therapy, which has demonstrated its ability to treat cancer in
preclinical models. Successful execution will get us to the clinic and enable us to begin helping
patients. The grant was awarded, in part, based on results of preclinical testing at Emory
University, which demonstrated that therapeutic administration of CM-JG01 halted tumor
progression in several preclinical models of disease.

Dr. Jacques Galipeau, MD FRCP(C), Don and Marilyn Anderson Professor in Oncology, Assistant
Dean for Therapeutics Discovery and Development, and Director of the Program for Advanced Cell
Therapy, at the University of Wisconsin in Madison, conducted the original research yielding this
therapy, and remains engaged in the preclinical development efforts. Dr. Galipeau noted, Our
chimeric cytokines have remarkable and novel immnuno-modulatory properties that could not have
been predicted based on the individual domains. Our initial results in melanoma models have
demonstrated clear efficacy, and were eager to advance this promising innovation into the clinic.

Skin cancer is the most common form of cancer in the United States. Melanoma is responsible for
the vast majority of skin cancer deaths with an estimated 87,110 new cases in 2017 and over 9,000
deaths each year. The average melanoma patient loses 20.4 years of potential life, according to the
US Centers for Disease Control and Prevention.

Research reported in this press release is supported by the National Cancer Institute of the National
Institutes of Health under award number R44 CA217365-01. The content is solely the responsibility
of the authors and does not necessarily represent the official views of the National Institutes of
Health.

About Celdara Medical, LLC:


Celdara Medical gives hope and health to patients by transforming academic innovations into
medicines with the potential to cure the worlds most challenging diseases. Celdara Medical is a
recognized leader with a rich stable of discoveries, developed in concert with premiere research
institutions in the US, EU, and beyond. We secure lasting partnerships with inventors and their
institutions, and provide the developmental, financial, and business acumen to bridge the gaps
between discovery and clinical impact. With robust funding options, operations in greater Boston,
NYC, and Washington, DC, growing affiliates in Seattle and Indianapolis, a wealth of opportunities
in our pipeline, and partnerships with industry leaders worldwide, Celdara Medical navigates the
path from science to medicine, accelerating innovation to improve human health.

Contact:
Celdara Medical, LLC
16 Cavendish Ct. DRTC
Lebanon, NH 03766
617 320 8521
kh@celdaramedical.com
http://www.celdaramedical.com